Literature DB >> 6795260

Antibody-independent interactions between Escherichia coli J5 and human complement components.

S J Betz, H Isliker.   

Abstract

With the characterization of an increasing number of molecules that are capable of activating the 1st component of the classical pathway of complement (C), the possibility that some Gram-negative bacteria may activate C1 independent of naturally occurring antibody has been reexamined. We have confirmed a previous report that purified C1 (the activated form of C1) can bind to certain strains of bacteria and it retains its enzymatic activity when thus bound. The availability of purified C1 in its precursor form has allowed us to extend these observations to the native C1 molecule. Using a semirough mutant of Escherichia coli, the galactose epimerase-deficient strain E. coli J5, we have examined the binding and activation of radiolabeled C1. J5 bound radiolabeled C1 in a dose-dependent manner and essentially all of the bound C1 was activated as judged by SDS-PAGE. The bacteria-C1 complex consumed purified C4 and C2 and the consumption of C2 was proportional to the C4 concentration. Subsequent addition of terminal C components C3-9 supplied as serum-EDTA caused a highly significant decrease in bacterial viability. These results demonstrate that C1 may bind to the bacterial membrane in such a manner as to initiate a bactericidal reaction. Therefore, antibody-independent binding and activation of C1 must be considered in the assessment of serum sensitivity of Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6795260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen.

Authors:  J E Schweinle; P J Hitchcock; A J Tenner; C H Hammer; M M Frank; K A Joiner
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

3.  Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae.

Authors:  F Clas; J R Golecki; M Loos
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

4.  A plasmid-encoded outer membrane protein, TraT, enhances resistance of Escherichia coli to phagocytosis.

Authors:  M E Agüero; L Aron; A G DeLuca; K N Timmis; F C Cabello
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

Review 5.  Bactericidal and bacteriolytic activity of serum against gram-negative bacteria.

Authors:  P W Taylor
Journal:  Microbiol Rev       Date:  1983-03

6.  Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.

Authors:  K A Joiner; M A Schmetz; M E Sanders; T G Murray; C H Hammer; R Dourmashkin; M M Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

7.  Sensitivity of Capnocytophaga species to bactericidal properties of human serum.

Authors:  M E Wilson; R Burstein; J T Jonak-Urbanczyk; R J Genco
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

8.  Antibody-independent interactions of fibronectin, C1q, and human neutrophils with Treponema pallidum.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

9.  Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.

Authors:  R W Vreede; J Leuvenink; A S Bouter; E C Brouwer; J H Marcelis; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

10.  Solid-phase C1q-directed bacterial capture followed by PCR for detection of Chlamydia trachomatis in clinical specimens.

Authors:  P Herbrink; H A van den Munckhof; H G Niesters; W H Goessens; E Stolz; W G Quint
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.